Business
GRAIL Reports First Quarter 2025 Financial Results
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025.
About this update from Grail, Inc.
[{"type":"text","content":"Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million","length":64,"tagName":"p","attribs":{}},{"type":"text","content":"GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial","length":101,"tagName":"p","attribs":{}},{"type":"text","content":"Cash Position of $677.9 Million Provides Runway Into 2028","length":57,"tagName":"p","attribs":{}},{"type":"text","content":"MENLO PARK, Calif., May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025.","length":233,"tagName":"p"},{"type":"image","alt":"GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)","displaySize":"","headline":null,"caption":"GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":76,"url":"https://media.zenfs.com/en/prnewswire.com/df6f1c041e7249704f56bfd0aaad45cf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LnMp0pobetiqZw3skecvAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/df6f1c041e7249704f56bfd0aaad45cf","width":400,"height":76}},"href":"https://mma.prnewswire.com/media/2460831/Grail_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Total revenue in the first quarter was $31.8 million, representing 19% growth year over year, and Galleri revenue was $29.1 million, representing 24% growth year over year. U.S. Galleri revenue was $28.7 million, representing 22% growth year over year. Net loss for the quarter was $106.2 million, which includes amortization of Illumina acquisition-related intangible items of $34.6 million. Gross loss was $19.9 million. Adjusted gross profit was $14.3 million, and adjusted EBITDA was $(98.7) million.1","length":505,"tagName":"p"},{"type":"text","content":""We are pleased with the continued U.S. commercial growth of Galleri, with more than 37,000 Galleri tests completed in the first quarter of 2025, as well as recent steps to streamline the test ordering process and increase test access," said Bob Ragusa, Chief Execu...